Avoro Capital Advisors GLUE Position
Exited4-Fund ConvergenceAvoro Capital Advisors exited their position in Monte Rosa Therapeutics, Inc. (GLUE) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
GLUE is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Oral MRT-2359 in 45 days (May 31, 2026), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 16.9% of float with 11.6 days to cover, indicating significant bearish positioning against the stock.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
16.9%
11.6 days to cover
Avoro Capital Advisors GLUE Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -3,725,000 | $0 |
| Q2 2025 | Decreased | 3,725,000 | -920,548 | $16.8M |
| Q1 2025 | Increased | 4,645,548 | +300,548 | $21.6M |
| Q4 2024 | Decreased | 4,345,000 | -1,445,236 | $30.2M |
| Q3 2024 | Increased | 5,790,236 | +1,255,236 | $30.7M |
| Q2 2024 | Held | 4,535,000 | — | $17.0M |
| Q1 2024 | Held | 4,535,000 | — | $32.0M |
| Q4 2023 | Held | 4,535,000 | — | $25.6M |
| Q3 2023 | Held | 4,535,000 | — | $21.7M |
| Q2 2023 | Increased | 4,535,000 | +210,000 | $31.1M |
| Q1 2023 | New | 4,325,000 | +4,325,000 | $33.7M |
Frequently Asked Questions
Does Avoro Capital Advisors own GLUE?
No. Avoro Capital Advisors exited their position in Monte Rosa Therapeutics, Inc. (GLUE) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own GLUE?
4 specialist biotech hedge funds currently hold GLUE, including Baker Bros. Advisors, BVF Partners, Cormorant Asset Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy GLUE?
Avoro Capital Advisors's position in GLUE was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's GLUE position increasing or decreasing?
Avoro Capital Advisors completely exited their GLUE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GLUECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →